Taysha Gene Therapies Inc. Revenue 2022–2025
Taysha Gene Therapies Inc. annual/quarterly revenue history and growth rate from 2022 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Taysha Gene Therapies Inc. revenue for the quarter ending March 31, 2026 was 0, a 100.00% decrease year-over-year.
- Taysha Gene Therapies Inc. revenue for the twelve months ending March 31, 2026 was 4.3 M, a 61.22% decrease year-over-year.
- Taysha Gene Therapies Inc. annual revenue for 2025 was 9.8 M, a 17.28% increase from 2024.
- Taysha Gene Therapies Inc. annual revenue for 2024 was 8.3 M, a 46.07% decrease from 2023.
- Taysha Gene Therapies Inc. annual revenue for 2023 was 15.5 M, a 517.55% increase from 2022.
- Taysha Gene Therapies Inc. annual revenue for 2022 was 2.5 M.
Taysha Gene Therapies Inc. (TSHA) — Frequently Asked Questions
Taysha Gene Therapies Inc. (TSHA) is a publicly traded US company. It has a market capitalization of $1.73B. In fiscal 2025 it reported revenue of $10M and net income of -$109M. Explore TSHA's stock price, financial statements, earnings history, margins and key ratios below.
What is Taysha Gene Therapies Inc.'s market cap?
Taysha Gene Therapies Inc. (TSHA) has a market capitalization of $1.73B.
What is the TSHA stock price?
TSHA trades at $5.40 (+0.75% on the day).
How much revenue does Taysha Gene Therapies Inc. make?
Taysha Gene Therapies Inc. reported revenue of $10M in fiscal 2025.
Is TSHA profitable?
In fiscal 2025, Taysha Gene Therapies Inc. reported net income of -$109M.